Intersect ENT (XENT) Reaches $28.33 After 6.00% Down Move; Transact Tech (TACT) SI Increased By 42.17%

July 17, 2017 - By Richard Conner

The stock of Intersect ENT Inc (NASDAQ:XENT) is a huge mover today! About 219,059 shares traded. Intersect ENT Inc (NASDAQ:XENT) has risen 79.98% since July 17, 2016 and is uptrending. It has outperformed by 63.28% the S&P500.The move comes after 8 months negative chart setup for the $841.09M company. It was reported on Jul, 17 by We have $26.63 PT which if reached, will make NASDAQ:XENT worth $50.47 million less.

Transact Tech Incorporated (NASDAQ:TACT) had an increase of 42.17% in short interest. TACT’s SI was 11,800 shares in July as released by FINRA. Its up 42.17% from 8,300 shares previously. With 14,800 avg volume, 1 days are for Transact Tech Incorporated (NASDAQ:TACT)’s short sellers to cover TACT’s short positions. The SI to Transact Tech Incorporated’s float is 0.2%. About 3,129 shares traded. TransAct Technologies Incorporated (NASDAQ:TACT) has risen 13.92% since July 17, 2016 and is uptrending. It has underperformed by 2.78% the S&P500.

TransAct Technologies Incorporated designs, develops and sells market-specific solutions, including printers, terminals, software and other products for transaction and other industries. The company has market cap of $65.51 million. The Firm operates through the segment, which includes design, development, assembly and marketing of transaction printers and terminals, and providing printer and terminal related software, services, supplies and spare parts. It has a 16.96 P/E ratio. The Company’s thermal, inkjet and impact printers and terminals generate labels and transaction records, such as receipts, tickets, coupons, register journals and other documents, as well as printed logging, and plotting of oil field and well drilling data.

Investors sentiment increased to 1.67 in Q4 2016. Its up 0.58, from 1.09 in 2016Q3. It increased, as 1 investors sold TransAct Technologies Incorporated shares while 8 reduced holdings. 6 funds opened positions while 9 raised stakes. 2.68 million shares or 0.78% more from 2.65 million shares in 2016Q3 were reported. Ancora Lc stated it has 61,058 shares or 0.03% of all its holdings. Bridgeway Capital Mgmt invested in 135,888 shares or 0.01% of the stock. Bancshares Of America De reported 504 shares. Northern Trust reported 24,071 shares. New York-based Teton Advisors has invested 0.09% in TransAct Technologies Incorporated (NASDAQ:TACT). 291,000 are held by Punch And Inv Mngmt. Dimensional Fund Advsrs L P owns 0% invested in TransAct Technologies Incorporated (NASDAQ:TACT) for 238,076 shares. Jacobs Levy Equity Management invested in 11,733 shares or 0% of the stock. Geode Cap Mngmt holds 0% of its portfolio in TransAct Technologies Incorporated (NASDAQ:TACT) for 33,579 shares. Tower Research Capital Limited Liability Corp (Trc) stated it has 0% in TransAct Technologies Incorporated (NASDAQ:TACT). Renaissance Tech Ltd Limited Liability Company has 387,001 shares for 0% of their portfolio. The Connecticut-based Lapides Asset Management Limited Liability Corporation has invested 0.13% in TransAct Technologies Incorporated (NASDAQ:TACT). National Bank & Trust Of Ny Mellon Corp owns 11,755 shares for 0% of their portfolio. Morgan Stanley accumulated 940 shares. Lsv Asset holds 0% or 28,700 shares.

Analysts await Intersect ENT Inc (NASDAQ:XENT) to report earnings on August, 1 after the close. They expect $-0.19 earnings per share, up 9.52% or $0.02 from last year’s $-0.21 per share. After $-0.23 actual earnings per share reported by Intersect ENT Inc for the previous quarter, Wall Street now forecasts -17.39% EPS growth.

Intersect ENT, Inc. is a commercial-stage drug-device company. The company has market cap of $841.09 million. The Firm develops drugs for patients with ear, nose and throat conditions. It currently has negative earnings. The Firm has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.